Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.
| Country | United States |
| IPO Date | Jun 4, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Mark Paul Lappe |
Contact Details
Address: 11025 North Torrey Pines Road La Jolla, California United States | |
| Website | https://inhibrx.com |
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739614 |
| CUSIP Number | 45720L107 |
| ISIN Number | US45720L1070 |
| Employer ID | 82-4257312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Chief Executive Officer, President & Chairman |
| Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President, Chief Financial Officer & Treasurer |
| Bonne Adams M.B.A. | Vice President of Operations |
| David Matly M.B.A. | Executive Vice President and Chief Commercial & Business Development Officer |
| Dr. Ashraf Amanullah Ph.D. | Executive Vice President, Chief Technical Operations Officer |
| Dr. Brendan P. Eckelman Ph.D. | Executive Vice President & Chief Scientific Officer |
| Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing & Commercial Planning |
| Dr. Josep Garcia Ph.D. | Executive Vice President & Chief Clinical Development Officer |
| Jeffrey J. Jensen | Executive Vice President & Chief Clinical Operations Officer |
| Leah Pollema J.D. | Vice President & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 424B3 | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 424B3 | Filing |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 07, 2024 | 4 | Filing |